相关临床试验
21
5 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
2000
进行中（未招募）
4
19.1%
已完成
11
52.4%
尚未招募
1
4.8%
招募中
4
19.1%
暂停
1
4.8%
暂无批准数据
- A new AI tool developed by University of Toronto and Mayo Clinic researchers can classify meningioma molecular groups from routine H&E pathology slides with up to 97% accuracy. - The deep learning models provide prognostic information in under an hour using only a laptop, eliminating the need for costly and time-consuming DNA methylation profiling. - The study, published in The Lancet Digital Health, analyzed tissue samples from over 600 patients and demonstrated AI-based recurrence predictions remained useful beyond traditional clinical factors. - Researchers have made the models publicly available as a decision support tool while prospective validation studies for wider clinical use are ongoing.
- Two major trials involving 4,232 participants found that Paxlovid does not reduce hospital admissions or deaths in vaccinated adults at higher risk of severe COVID-19, despite helping them recover faster. - The UK PANORAMIC trial showed median recovery time of 14 days with Paxlovid versus 21 days with usual care, while the Canadian CanTreatCOVID trial found recovery at 6 days versus 9 days respectively. - Hospitalization rates remained very low in both trials, with no statistically significant differences between Paxlovid and usual care groups across either study. - These findings provide crucial evidence for cost-effective targeting of Paxlovid treatment in today's highly vaccinated populations where severe COVID-19 outcomes are already rare.
- Researchers at Université de Montréal have identified SLAMF6 as a novel immune checkpoint molecule that functions autonomously on T cell surfaces to suppress anti-tumor immunity. - Unlike PD-1 and CTLA-4, SLAMF6 operates through cis homotypic interactions on T cells themselves, accelerating T cell exhaustion independently of tumor cell interactions. - Monoclonal antibodies targeting SLAMF6 demonstrated enhanced T cell activation and tumor growth suppression in preclinical models, offering potential for patients resistant to current checkpoint inhibitors. - The discovery represents a paradigm shift toward addressing intrinsic immune regulatory checkpoints and may enable combination therapies that surpass current immunotherapy limitations.
- Major international medical research funders have signed a joint statement committing to implement WHO standards for strengthening clinical trial systems globally. - The initiative aims to integrate clinical trials into sustainable national infrastructure while improving trial design and ensuring representative patient populations. - Funders will require trials to be registered in public registries, publish results within 12 months, and meet transparency standards for data sharing. - Within six months, signatories will develop measurable indicators to track progress and ensure accountability across the global research community.
- University of Alberta researchers are conducting clinical trials across seven Canadian sites for a precision diet tool that analyzes gut microbiome to optimize nutrition for inflammatory bowel disease patients. - The AI-powered system cultures gut microbes with different carbohydrates from stool samples and creates personalized dietary recommendations, showing increased remission rates in IBD patients within weeks to months. - The $10-million Weston Family Foundation-funded research has demonstrated benefits beyond IBD, with healthy participants reporting improved cardiovascular health and overall wellbeing. - The precision diet approach focuses on optimizing nondigestible carbohydrates and emphasizes whole food consumption, with clinical availability expected within three years.
- MedMira has launched a clinical trial to evaluate its Multiplo TP/HIV rapid test for self-testing use in Canada, with first participants enrolled at sites in Victoria and Toronto. - Health Canada approved bypassing the typical non-professional use step, allowing MedMira to proceed directly to self-testing application based on previously submitted clinical data. - The trial addresses urgent public health needs as new HIV diagnoses in Canada surged over 35% from 2022 to 2023, while syphilis cases nearly doubled from 2018 to 2023. - The Multiplo test provides immediate results from a finger-prick blood sample, enabling private at-home testing for both HIV and syphilis simultaneously.
- A small-scale gene therapy study for Fabry disease enabled three of five male patients to discontinue costly enzyme-replacement therapy, generating $3.7 million in savings against $4 million research costs. - The experimental treatment uses bone marrow stem cells to deliver replacement copies of faulty genes, with patients maintaining elevated enzyme production five years post-treatment. - Researchers plan to expand the study to 25-30 patients including women over two to three years, as the current therapy requires bi-weekly treatments costing $300,000 annually per patient. - The gene therapy demonstrated a favorable safety profile with only two minor side effects related to preparatory chemotherapy rather than the gene therapy itself.
- A multicenter clinical trial found that dapagliflozin combined with insulin reduced kidney disease risk and improved health outcomes in 98 adolescents with type 1 diabetes over 16 weeks. - The combination therapy demonstrated significant improvements including 8.8 ml/min reduction in glomerular filtration rate, 0.47% decrease in HbA1c, and 2.8 kg weight reduction compared to placebo. - Results showed similar safety profiles between treatment groups with only one mild case of diabetic ketoacidosis in the dapagliflozin group, suggesting the therapy could inform new early intervention strategies. - The study addresses a critical gap in adolescent diabetes research, as this age group is often underrepresented in clinical trials despite facing unique challenges with hormonal changes and treatment management.
- Avicanna Inc. has entered a Sponsored Research Agreement to fund a Phase II clinical study evaluating oral cannabis extracts for osteoarthritis pain, scheduled to begin in Fall 2025. - The multi-center, blinded, randomized, placebo-controlled trial will be led by Dr. Hance Clarke at the University Health Network and is funded by a Canadian Institutes of Health Research grant. - The study aims to assess the feasibility of a larger definitive trial by evaluating patient enrollment, protocol adherence, and data completeness for CBD and THC capsules in treating hip and knee osteoarthritis pain.
- Canadian researchers at McMaster University have begun phase-2 clinical trials for AeroVax, an innovative inhaled COVID-19 vaccine that directly targets the lungs and upper airways where infection begins. - The $8M CIHR-funded study aims to recruit 350 participants across Hamilton, Ottawa, and Halifax, testing a needle-free alternative that preliminary data suggests induces stronger immune responses than traditional injected vaccines. - This entirely Canadian-developed vaccine could potentially reduce recurrent infections by providing robust protection at the infection site, with plans to advance to phase-3 efficacy trials following successful completion.
